https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)2011-06-17 11:41:282019-07-17 11:42:05Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:652011-06-17 00:00:002019-02-15 08:45:33Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-17 / Cancer Immunol. Immunother. 2011 Oct;60(10):1497-502
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-17 / Cancer Immunol. Immunother. 2011 Oct;60(10):1497-5022011-06-17 00:00:002019-02-15 08:45:34Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-912011-06-15 00:00:002019-02-15 08:52:52Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / J Cancer 2011;2:357-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / J Cancer 2011;2:357-92011-06-15 00:00:002019-02-15 08:52:49Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-10092011-06-15 00:00:002019-02-15 08:52:50Recent advances in immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)2011-06-06 11:53:442019-07-17 11:54:11Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)2011-06-05 00:00:002011-06-05 00:00:00Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 9541)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 9541)2011-06-05 00:00:002011-06-05 00:00:00Pilot immunotherapy trial in high-risk pediatric sarcomas.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)2011-06-04 11:42:372019-07-17 11:43:10Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
